Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513604 | 0.87 | TRPV1 (0.83) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL6156938 | 0.87 | HDAC3 (0.66) | TRPV1PTGS1NPC1RAB9ALMNA | |
| SCHEMBL3711352 | 0.84 | HDAC3 (0.70) | TRPV1NPC1RAB9AMAPTMEN1 | |
| SCHEMBL4188342 | 0.83 | NPC1 (0.52) | NPC1RAB9AMAPTMEN1LMNA | |
| SCHEMBL27759009 | 0.83 | LMNA (0.76) | TRPV1PTGS1NPC1RAB9AMAPT | |
| SCHEMBL4247052 | 0.82 | NPC1 (0.86) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL2104851 | 0.82 | PTPN1 (0.68) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26985985 | 0.81 | MAPT (0.58) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL674439 | 0.81 | HDAC6 (0.82) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL2064051 | 0.81 | TRPV1 (0.73) | TRPV1PTGS1NPC1RAB9ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | claimed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| EP-3237407-B1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | SMA THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9546163-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | TRPV1 4222/4885PTGS1 774/4885NPC1 2748/4885 |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | TRPV1 4222/4885PTGS1 774/4885NPC1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.